Renal blood flow (RBF) autoregulation was investigated in anesthetized C57Bl6 mice using time-42 and frequency-domain analyses. Autoregulation was reestablished by 15 sec in two stages after a 25 43 mmHg step increase in perfusion pressure (RPP). The renal vascular resistance (RVR) response did 44 not include a contribution from the macula densa tubuloglomerular feedback mechanism (MD-TGF). 45
INTRODUCTION 64
Most vascular beds regulate blood flow according to metabolic conditions to provide adequate 65 nutrient delivery and effective waste removal. Control of renal blood flow (RBF) is unique among 66 peripheral vascular beds as the principal goal is not to satisfy metabolic demands but rather to stabilize 67 glomerular capillary pressure at a level that provides an adequate glomerular filtration rate (GFR). This 68 is achieved by an efficient autoregulatory mechanism(s) that adjusts glomerular afferent arteriolar 69 diameter in response to fluctuations in renal perfusion pressure (RPP). Of equal importance, this 70 process protects glomerular capillaries from excessive pressures that can cause barotrauma, 71 glomerular injury, and renal failure. Several intrinsic mechanisms regulate renal vascular resistance 72 (RVR) in response to changes in RPP (3; 13). In common with most organs, changes in RPP invoke an 73 intrinsic myogenic mechanism in the vascular smooth muscle cells (VSMC) of renal resistance vessels 74 which stabilizes downstream capillary pressures. The unusually high efficiency of blood flow 75 autoregulation in the kidney may be due to an exceptionally strong myogenic mechanism and perhaps 76 the unique contribution of additional mechanisms involving tubuloglomerular feedback (TGF) such as 77 distal tubular macula densa (MD) cell signaling to the afferent arteriole, termed MD-TGF (3; 13). 78
Classically, autoregulation has been assessed by determining RBF responses to progressive 79 increases or decreases in RPP with pressure steps lasting 1-2 min to define steady-state 80 autoregulation (13; 15; 33). This produces a static, integrated autoregulatory response that provides an 81 index of overall efficiency, but it does not differentiate between the relative contributions of individual 82 mechanisms. Alternative approaches have analyzed dynamic components of the RPP/RBF relationship 83 in either the time-or the frequency-domain to isolate the contributions of multiple mechanisms 84 operating in the kidney. The results of these dynamic analyses have revealed distinct components 85 adjusting RVR or vascular admittance based on different time-constants of the more rapid myogenic 86 mechanism and the slower MD-TGF mechanism. In the time domain, the increases in RVR to an abrupt 87 step increase in RPP reveals distinct phases or stages in the rate of the response that have been 88 attributed to the sequential operation of the myogenic mechanism followed by input from MD-TGF. In 89 the frequency domain, spectral analysis of relative changes in RBF vs. RPP (admittance gain) 90 distinguish between the operation of the myogenic mechanism at the upper end of the autoregulatory 91 frequency range (0.08 -0.25 Hz) and the MD-TGF mechanism at the lower end of the frequency range 92 (0.01 -0.02 Hz) (13; 15; 18; 33). In addition, both approaches have advanced evidence suggesting the 93 operation of a third and perhaps even a fourth mechanism (13; 34; 36). 94
The relative contributions of the myogenic and MD-TGF mechanisms to RBF autoregulation and 95 their interactivity are important questions that remain somewhat controversial. In general, most transfer 96 diaphragm connected to a Ling Shaker motor (Ling Dynamic Systems, Model 203). Random pressure 193 fluctuations in the syringe were produced by driving the Ling motor with a white noise signal after 194 conditioning with a 2 Hz low pass filter. The resulting motion of the syringe plunger was delivered to the 195 aorta via tension on the snare to produce random changes in RPP. Digitized and filtered RPP and RBF 196 signals were collected for 35 min and stored on disk for offline analysis. 197
The RPP and RBF time-series data were processed by fast Fourier transformation (FFT) using 198 repetitive 4096 sample segments that were normalized to zero mean and de-trended. According to 199
Welch's method (92), data segments were overlapped by 50% to reduce noise and variance. Segments 200 were tapered at each end using a Kaiser window with a shape factor set to approximate a normal 201 between RBF and RPP spectra represents the fraction of the variance of the RBF signal at a given 213 frequency that can be accounted for on the basis of a linear operation on the RPP signal at that 214 frequency. Coherence would be unity if there were no variables other than RPP affecting RBF, 215 assuming no measurement error. 216
Experimental Protocols 217
Experiments were divided into three periods. Control data were obtained in the first period followed 218 by administration of the NOS inhibitor L-NAME (25 mg/kg iv) in the second period. In the third period, 219 the cell-permeable SOD mimetic tempol was infused (4 mg/kg/min iv) to produce suppression of 220 superoxide activity during NOS inhibition. A 20 min stabilization period was allowed after L-NAME 221 administration and the start of tempol infusion. In time-domain studies, four RPP steps were performed 222 in each period. Results were averaged in each period to provide three averaged responses for each 223 animal. The same basic protocol was followed in frequency-domain experiments. Data were collected 224 at 10 Hz for 35 min in the control, L-NAME and combined L-NAME + tempol periods. Derived data from 225 transfer function analyses for each animal were averaged from the 8 data segments extracted from 226 each collection period. 227
Our interpretation of results obtained during L-NAME is based on its inhibitory action on NOS and 228 consequent reduction in NO production and local concentration of NO. L-arginine analogs such as L-229 NAME or L-NNA are known to act as specific inhibitors of NOS isoforms and NO production in health 230 inhibition also attenuates acetylcholine-induced urinary excretion of cGMP, an index of renal NOS 238 activity, and the concomitant renal vasodilation (8; 82). These effects are independent of the constrictor 239 actions of angiotensin II or the sympathetic nervous system, at lease in conscious, unstressed animals 240 (7; 46; 73). 241
The contribution of MD-TGF to the autoregulatory response was tested in other mice by blocking 242 MD-TGF with ureteral obstruction (UO) during an osmotic diuresis. To induce the diuresis, a 10% wt/vol 243 solution of mannitol in 0.45% saline was infused iv at a rate of 20 µl/min. When urine flow had 244 increased from the basal level of 1-2 μl/min to 20-30 μl/min, the right ureter was tied off at the renal 245 pelvis. After ten min for equilibration, experiments proceeded with step increases or random 246 fluctuations in RPP. 247
In a separate series of experiments, the RPP step protocol was performed before and during iv 248 infusion of AVP titered to produce an increase in RPP equal to that caused by L-NAME treatment (300 249 ng/min at 30 μl/min). These data controlled for effects of increased RPP caused by L-NAME that were 250 unrelated to NO inhibition. A second series tested the direct effect of the hypotensive action of tempol 251 on the autoregulatory response after treatment with L-NAME in the frequency domain. In these mice, 252 tempol was omitted from the third period and instead the aortic snare was tightened to reduce mean 253 RPP to the control level. Random fluctuations were induced at this mean pressure in the manner 254
described. 255

Data Analysis: Time domain 256
The increase in RVR following a RPP step was expressed as the percent return to 100% 257 autoregulation based on the RBF and RPP values prior to the RPP step. The resulting RVR response 258 curves were analyzed up to 60 sec following the RPP step. An initial rapid decrease and increase in 259 RVR over the first 0.7 sec were excluded from the analysis as this has been identified as a passive 260 response to the initial surge in pressure within the vasculature (34; 96). Many studies on rodents have 261
shown that the restoration of RBF following the RPP step occurs in discrete stages that can be 262 attributed to the operation of individual components in the autoregulatory response (27; 34; 96). Two 263 distinct stages were evident in the RVR responses in our animals, with 100% efficiency generally 264 occurring during the second stage about 15 sec after the RPP increase. The slopes for each stage and 265 transition points were analyzed by multiple regression analysis to produce best fit-data using 266 commercial software (Prism 6.5, Graphpad software). To provide unambiguous identification of slopes 267 and time points, the transition point between stages 1 and 2 was constrained to occur no sooner than 1 268 sec after the RPP step. A second transition point was set to occur no earlier than 15 sec which 269 provided a value corresponding to the end of stage 2. Slopes and transition points in each period were 270 compared by 2 way ANOVA or by t-test where appropriate. The overall autoregulatory efficiency was 271 assessed by comparisons of mean RBF during 60 sec of reduced RPP immediately prior to the RPP 272 step and mean RBF between 90 and 120 sec after the RPP step. The efficiency of steady-state RBF 273 autoregulation was equated with the efficiency recorded between 50 and 60 sec. 274
Data Analysis: Frequency domain 275
The imposed fluctuations in RPP required persistent tension on the aortic snare. Thus, mean RPP in 276 these experiments was approximately 10 mmHg lower than the basal or spontaneous RPP in the 277 absence of aortic occlusion. 278
Transfer function analyses of RPP and RBF were performed on data derived from the real and 279 imaginary components of their cross spectrum, which constitute the co-spectrum and quadrature 280 spectrum, respectively. Phase angle was calculated from the arctangent of the co-spectrum and 281 quadrature spectrum at each frequency step and expressed in degrees. Admittance gain was 282 calculated as the square root of summed squares of the co-spectrum and quadrature spectrum and 283 adjusted to correct for the large difference between raw RPP and RBF values. The correction factor 284 was calculated as the ratio of average fluctuation amplitudes in untransformed RPP and RBF traces. 285
Coherence was calculated as the squared cross-spectral density factored by the product of RPP and 286 RBF autospectral densities at each frequency step and expressed on a ratio scale between 0 and 1. 287
Comparisons of the slopes of admittance gain in the 0.06 -0.2 Hz frequency range associated with 288 the myogenic mechanism were made using a linear frequency scale. This provided more resolution and 289 the opportunity to perform multiple regression analyses of the slope values using the same procedure 290 as described for the RPP step response. The minimum value for the transition point between two 291 stages was set to occur at no less than 0.155 Hz. 292
Chemicals used: Pentobarbital, L-NAME, tempol, and AVP were obtained from Sigma Chemical Co. 293
RESULTS
294
Average body weight of all animals in the study was 28.2±0.5 g with a right kidney weight of 295 0.216±0.005 g (n=40). During control conditions, mean AP was 105±2 mmHg and RBF averaged 296 8.58±1.51 ml/min/g KW. 297
The mean autoregulatory efficiency curve of RVR following a 25 mmHg step increase in RPP during 298 the control state is shown in Fig. 1A . The trace shows the time course for re-establishment of 299 autoregulation over the first 60 sec after the RPP step from 80 to 105 mmHg. The RVR response curve 300 had several distinct phases beginning with an immediate decline for 0.3 sec, followed by a sharp 301 rebound between 0.3 and 0.7 sec (Fig. 1A inset) . These initial RVR changes have been attributed to 302 passive distension and subsequent elastic recoil of the vasculature caused by the immediate impact of 303 the RPP increase (96). The passive nature of this immediate response is confirmed by its persistence 304 after elimination of the active autoregulatory response by calcium channel blockers (34). The active 305 autoregulatory RVR response was composed of two distinct stages with a transition at ~5 sec (Fig. 1) . 306
Each stage contributed ~50% of the RVR response leading to perfect autoregulation that was attained 307 by ~13 sec. The second stage continued beyond 100% and ended at 19 sec after the RPP step with a 308 total efficiency of 115%. Mean slope values for the two stages, transition points and completion times 309 for the second stage are given in Table 1 . The pre-step RPP and RBF values were mean values over 310 60 sec immediately before the RPP step. The post-step RPP and RBF values were recorded between 311 90 and 120 sec after the RPP step. It is clear that that RBF was efficiently autoregulated over this time 312 frame. The fact that RBF ended up slightly lower than the pre-step starting level suggests an element of 313
super-autoregulation. 314
To determine the contribution of MD-TGF to the RVR response in the time-domain, similar 315 experiments were performed after inhibition of MD-TGF by means of a 10% mannitol diuresis combined 316 with complete ureteral occlusion (mannitol/UO) (18). As is shown in Fig. 1B , inhibition of MD-TGF did 317 not change the general shape of the RVR response, which achieved 100% efficiency by 13-14 sec. 318 Thus, the initial two stages of the autoregulatory adjustments in RVR persisted after suppression of 319 MD-TGF and are most likely exclusively due to a myogenic mechanism(s). In the absence of MD-TGF, 320 each stage still accounted for ~50% of perfect autoregulation. Nevertheless, it is noteworthy that there 321 was a 28% increase in the slope of stage 1 (P<0.001), whereas the slope of stage 2 decreased 322 insignificantly (Table 1) . Unlike the control state, during mannitol/UO the final autoregulatory RVR 323 response did not exceed 100% of perfect autoregulation (Fig. 1B) . These findings suggest that MD-324 TGF exerted a small inhibitory effect on the initial myogenic response, probably due to a dilatory action 325 of MD-TGF during the reduced RPP that tended to offset the initial RVR increase when RPP was 326 abruptly increased. Also, the MD-TGF mechanism appeared to be implicated in an RVR overshoot 327 beyond 100% efficiency that was commonly observed between 15 and 60 sec in trials when MD-TGF 328 was active, contributing to a small increase in RVR after completion of the myogenic response. the RBF and RPP signals in this range was too low to permit confident interpretation. 339
We observed that mannitol/UO did not affect the slope of the myogenic response between 0.2 to 340 0.06 Hz, whereas the change in admittance gain associated with MD-TGF activity at lower frequencies 341 was virtually eliminated (Fig. 1C) . Effective abrogation of MD-TGF by mannitol/UO was also evident in 342 the elimination of a pronounced increase in phase angle present in the control state at frequencies 343 associated with MG-TGF activity (Fig. 1D ). An increasing phase angle in this frequency range indicates 344 an increasing independence of RBF from the passive effects of RPP fluctuations, consistent with strong 345 MD-TGF activity. These findings extend previous studies showing that full autoregulatory efficiency can 346 be achieved by myogenic mechanisms without the involvement of MD-TGF (18; 30). 347
To assess the role of NOS inhibition on the dynamic characteristics of the renal myogenic 348 mechanism(s), the RPP step protocol was repeated after L-NAME inhibition of NOS activity and NO 349 production. Dramatic effects were observed in both the time-and frequency domain experiments. Renal 350 autoregulatory efficiency in the time-domain increased to 170% within 2 sec after the RPP step (Fig. 2) . Additional experiments tested the notion that the effects of NOS inhibition were due, at least in part, 358 due to the enhanced vasomotor activity of O 2 -. To this end, we infused the cell-permeable SOD mimetic 359 tempol during L-NAME inhibition of NOS. Slopes and transition points of the RVR responses to the step 360 change in RPP during control, L-NAME, and L-NAME + tempol periods are shown in Fig. 2 and are 361 summarized in Table 2 . In essence, superoxide inhibition with tempol reversed the stimulatory action 362 noted during NOS inhibition on the initial rate of the myogenic autoregulatory response (stage 1) and 363 virtually eliminated the oscillations in RVR following the RPP step, consistent with a major potentiating 364 action of O 2 -on stage 1 of myogenic vasoconstriction in the absence of NO. Stage 2 of the myogenic 365 response was similar to that observed during control conditions. The data indicate that that NO 366 synthesis inhibition leads to an exaggerated myogenic response. The exaggerated myogenic response 367 was normalized by tempol, an effect suggesting an exaggerated vasoconstrictor action of O 2 -during 368
NO synthase inhibition. 369
The increase in basal AP from 105 to 128 mmHg after L-NAME is a consideration as this alone 370 might influence the rate of the autoregulatory response (90). This was tested by repeating the RPP step 371 in a separate group of mice before and during intravenous infusion of AVP at a rate that produced a 372 stable increase in AP similar to that produced by L-NAME. The general pattern of the autoregulatory 373 response in these AVP-infused mice at 126 mmHg was not different from the control response seen at 374 the basal pressure of 100 mmHg and no oscillations in RVR occurred following the RPP step. These 375 results are presented in Fig. 3 and Table 3 . There was an increase in the slope of stage 1 from 17.7 to 376 28.6 %/sec (P<0.001). This may reflect a relatively small enhancement of the myogenic response due 377 to the increased RPP as compared to the effects of NOS inhibition with L-NAME on the stage 1 slope 378 (increase from 15.5 to 188.3 %/sec) when RPP increased to a similar extent. The duration of stage 1 379 was reduced after AVP leading to a transition to stage 2 at 2.8 sec vs. 4.2 sec during control conditions. 380
This also might reflect a response to the higher basal RPP. It is notable that there were reciprocal 381 percent changes in the slope and end point of stage 1 after AVP, suggesting that a similar degree of 382 vasoconstriction was achieved over a shorter time period which accounted for ~60% of full 383 of admittance gain in the myogenic region was clearly increased by L-NAME and resulted in a reduction 394 in relative gain from 2.0 at 0.2 Hz to 0.4 at 0.06 Hz, a gain value that in the control state required the 395 combined operation of MD-TGF and myogenic mechanisms. As in the time-domain, the increased 396 magnitude of the myogenic response was largely reversed by tempol (blue trace), which also reduced 397 the amplitude of the resonance peak at 0.25 Hz close to control levels. Inspection of the admittance 398 gain trace between 0.02 and 0.001 Hz after tempol reveals the reappearance of a characteristic MD-399 TGF signature that was suppressed during L-NAME alone. This suggests that the absence of MD-TGF 400 activity following L-NAME treatment was likely due to enhanced myogenic contractility rather than 401 inhibition of the MD-TGF signaling mechanism per se. The mean RPP and RBF values for these 402 experiments are presented in Table 4 . 403
Phase and coherence relationships between RPP and RBF are shown in Fig. 4C and 4D . The 404 phase transition between 0.2 and 0.06 Hz during control conditions was strongly accentuated after 405 NOS inhibition, indicating the increased strength of the myogenic mechanism in this frequency range. 406
This was also the case in the MD-TGF range (<0.025 Hz) after L-NAME, albeit less pronounced, which 407 is consistent with the loss of the MD-TGF signature in admittance gain after L-NAME. Interestingly, the 408 phase relationship between RPP and RBF after tempol was restored to the control level, an observation 409 consistent with the apparent restoration of MD-TGF seen in the admittance gain traces. In the control 410 and L-NAME + tempol periods, coherence was greater or equal to 0.5 for frequencies above 0.009 Hz, 411 thus providing strong confidence for the derived parameters at this frequency and above. Coherence 412 was less well sustained at low frequencies during L-NAME alone coincident with the low admittance 413
gain. This indicates a more complex, non-linear relationship between RPP and RBF, perhaps fueled by 414 the enhanced action of superoxide on the vascular contractile response. 415
It is reasonable to expect that the distinct stages apparent in the myogenic response during control, 416 L-NAME, and L-NAME + tempol periods in the time domain are also evident in the frequency-domain. 417
To assess this prediction, the section of admittance gain associated with the myogenic response in the 418 frequency domain (0.06 -0.25 Hz) was magnified in Fig. 4B and plotted on a linear frequency axis to 419 facilitate comparisons of the slopes. In view of the two stages characterizing the myogenic mechanism 420 in the time-domain, each admittance gain trace was analyzed using multiple linear regression to 421 evaluate differences in slopes and transition points. The transition points for each period were 422 constrained to occur after 0.15 Hz. The resulting best-fit regression lines are shown as white lines in 423 Fig. 4B , and the slopes and transition points are summarized in Table 4 . Two stages were identified in 424 the myogenic frequency range. It is striking that the transition point between stages (identified by 425 circles) was not statistically different among the three experimental periods and that the slopes of 426 myogenic responses in the low frequency range (labeled as stage 2) were the same during the three 427 conditions. The admittance gain for the higher frequency range between 0.15 and 0.25 Hz, labeled 428 stage 1, showed a significantly increased slope above control in the L-NAME group, an effect 429 normalized by tempol treatment. We postulate that these two stages in the myogenic response in the 430 frequency domain correspond to the two stages identified in the time-domain. In each case, the slope of 431 stage 1 only was augmented by inhibition of NO and inhibited by suppression of O 2 -. In the time-432 domain, this was the initial stage after the increase in RPP, while in the frequency domain the 433 responsive region was restricted to the higher frequencies of the myogenic range (stage 1 in Fig. 4B) . 434
By this reasoning, stage 2 in Fig. 4B was comparable to stage 2 of the myogenic response in the time 435 domain, both of which were insensitive to L-NAME and tempol. 436
Tempol treatment after L-NAME during spectral analysis experiments reduced RPP to the control 437 level seen before L-NAME. This is a potential confounding factor in the interpretation of these data as 438 the RPP drop alone could alter the admittance gain (71; 90). To test this, the admittance gain was 439 determined in other animals before and during NOS inhibition with L-NAME, followed by a period in 440 which fluctuations in RPP were reduced to the mean level recorded during tempol treatment. The 441 admittance gain, phase angle, and coherence of the RPP/RBF relationship for these experiments are 442 presented in Fig. 5 . The forced reduction in mean RPP from 118 to 79 mmHg during NOS inhibition 443 with L-NAME caused a small nonsignificant reduction in the magnitude of the admittance gain from 444 between RPP and RBF after L-NAME were similar at high and normal RPP levels. 448
DISCUSSION 449
Our study provides a comprehensive description of the dynamic characteristics of blood flow 450 autoregulation in the mouse kidney using a novel combination of time-and frequency-domain analyses. 451
We provide new evidence that autoregulatory adjustments in RVR following a step increase in RPP are 452 essentially complete within 15 sec and are mediated exclusively by the myogenic mechanism(s). This 453 intrinsic, rapid myogenic response involves two phases or stages that do not require MD-TGF to 454 achieve a complete autoregulatory response. Stage 1 produces a 50-60% increase in RVR by 3 sec 455 and stage 2 accounts for the remaining 40-50% by 13 sec. A slight overshoot was complete by 18 sec. 456
In addition, on the basis of responses to L-NAME and tempol our data implicate interactive roles for 457 superoxide and nitric oxide in the modulation of dynamic elements in myogenic RBF autoregulation in 458 the healthy kidney. As might be expected, inhibition of NO synthesis accentuates the autoregulatory 459 response, presumably by reducing NO-mediated vasodilation. However, subsequent dismutation of the 460 vasoconstrictor O 2 -restores the original the speed and strength of the myogenic constrictor response 461 despite continued NO synthase inhibition. In this regard, our data support the hypothesis that the 462 predominant action of NO is to suppress a O 2 -mediated vasoconstrictor effect, perhaps secondary to 463 quenching O 2 -, rather than exerting a direct vasodilatory action. A new finding is that these interactions 464 are primarily targeted to the initial, most rapid phase of the myogenic mechanism and have little 465 influence on the second slower phase of myogenic vasoconstriction, or on overall, steady-state RBF 466
autoregulation. 467
An abrupt increase in RPP has been used previously to investigate dynamic aspects of RBF 468 autoregulation in dogs, rats and mice. A study on anesthetized dogs showed that RBF returned to the 469 control level 25 sec after a 40 mmHg step increase in RPP (31) . Similar to our mouse results, Marsh 470 and associates showed that RBF autoregulation in the rat was complete 15 sec after a 10-20 mmHg 471 RPP step (96). In their study, an immediate passive response in RVR lasted less than 1 sec followed by 472 an initial active stage which produced a 50% increase in RVR at ~3 sec and a subsequent slower 473 increase in RVR that completed the autoregulatory response by 15 sec (96). Measurements of tubular 474 fluid flow changes in the early distal tubule after the RPP step led them to conclude that the rather 475 sluggish MD-TGF response could not operate within the time frame of these autoregulatory RVR 476 responses. Daniels and Arendshorst reached a similar conclusion based on the time delay required for 477 activation and completion of the MD-TGF mechanism (17). Using stop-flow micropuncture 478 methodology, these investigators found a 15 sec delay in the single nephron MD-TGF response 479 following a step change in late proximal tubule perfusion. The MD-TGF response attained 50% of its 480 eventual maximum 27 sec after the increase in perfusion rate, which is too slow to participate in the 481 autoregulatory response. This is in accordance with an earlier study showing no measurable effect of 482 MD-TGF inhibition by UO on the static RBF autoregulatory curve (18). In the exposed juxtamedullary 483 preparation of rats, autoregulatory adjustments of afferent arteriolar diameter responded quickly to a 484 step increase in RPP (86). The decrease in diameter took place between 6 and 24 sec when MD-TGF 485 was active and between 6 and 13 sec during abrogation of MD-TGF by papillectomy. Thus, MD-TGF 486 complimented the myogenic response only after 13 sec. In the hydronephrotic rat kidney which lacks 487 tubules and thus any MD-TGF, afferent arteriolar diameter responses to a step increase in RPP were 488 complete within 15 sec (56). physiological signals compared to the slower second stage that is relatively insensitive. This is similar 500 to earlier observations in other vascular beds that identified two stages in the myogenic response. In 501 that case an initial, rate-sensitive, mechanism preceded a second static response that was not 502 influenced by the rate of pressure change (4; 5; 21). 503
Our data are consistent with earlier reports showing effective renal autoregulatory response to an 504 abrupt increase in RPP that is complete in 15-25 sec after the RPP step in multiple species. Moreover, 505 the data indicate that this is due to a rapid myogenic mechanism without significant contribution from 506 the slower MD-TGF mechanism. In contrast, rodent studies by Just and normal rats, whereas the first two stages persisted in roughly the same time intervals as during 512 control conditions (34-36). Thus, according to our interpretation, their data are consistent with the most 513 rapid two phases being associated with the myogenic mechanism, while the third mechanism is due to 514 MD-TGF. However, their assumption that the myogenic mechanism takes place between 1 and 4-7 sec 515 and that the MD-TGF begins at 4-7 sec and ends at 25-30 sec (20; 36; 37) is at variance with our 516 conclusion. The persistence of an autoregulatory response in the 5-20 sec time window during 517 furosemide inhibition of MD-TGF was interpreted as an undefined mechanism independent of the 518 myogenic and MD-TGF mechanisms, whereas our data clearly establish that RBF autoregulation in this 519 time window is achieved by the second stage of the myogenic response. Drummond et al. also find a 520 similar second stage of the RVR response when MD-TGF is inhibited by extracellular fluid volume 521 expansion (25). It is likely that a marked difference in the time interval required for the completion of 522 RBF autoregulation is the basis of the divergent conclusions, but the underlying reason for the 523 difference is not known. 524
As previously described (34), our time-domain analysis shows a modulatory action of MD-TGF on 525 the rate of the myogenic mechanism such that the latter was increased when MD-TGF was inhibited. 526
This is likely a function of the experimental design in which reduced RPP prior to the step increase in 527 RPP reduces flow to the macula densa and elicits a vasodilatory signal from the MD-TGF mechanism 528 (34). This persists during the first seconds following the step increase in RPP and tends to oppose the 529 initial stage of the rapid increase in RVR mediated by the myogenic mechanism. This was not apparent 530 in the frequency domain where admittance gain associated with the myogenic mechanism was not 531 previous studies with the caveat that differences might be expected with respect to species used, state 553 of anesthesia, the kidney preparation, and type of AP fluctuations employed. 554
The efficiency of steady-state RBF autoregulation, based on the plateau phase, is not affected by 555 NOS inhibition (6; 8; 20; 35; 58; 67), whereas the dynamic components of the myogenic mechanism 556 are clearly influenced by the presence and absence of NO. Changes in the time-domain include an 557 accelerated and pronounced increase in RVR with obvious oscillations (Fig 2, (19; 20; 35; 95) ). In the 558 frequency-domain, L-NAME caused an exaggerated resonance peak at 0.25 Hz and a stronger 559 myogenic response identified by an accelerated reduction in admittance gain in the myogenic 560 frequency range (Fig 4, (79; 80; 87; 90; 91)). Thus, NO inhibition did not affect overall steady-state RBF 561 autoregulation, but did markedly augment the rate at which it is achieved. The potentiation of an 562 intrarenal mechanism(s) appears to be independent of hypertension per se as the myogenic response 563 is not altered markedly by angiotensin II, AVP or phenylephrine-induced hypertension of a magnitude 564 similar to that of NOS inhibition (Fig. 3, (20; 35; 71; 80) ). Multilinear analysis of the RVR response to 565 the RPP step revealed that the target of NOS inhibition was the initial stage of the myogenic response 566 which became accelerated and stronger and was converted to oscillations. Such oscillations became 567 superimposed onto the second stage with diminishing amplitude while the fundamental mean slope of 568 the second stage remains unchanged. This was also evident in the frequency-domain when NOS 569 inhibition strongly increased the slope of admittance gain at the higher end of the myogenic range and 570 amplified the resonance peak at 0.25 Hz. At lower frequencies in the myogenic range, between 0.06 571 and 0.1 Hz, the slope of admittance gain was unaffected by NOS inhibition. A similar two stage 572 response of admittance gain after L-NAME was seen in rats by Cupples and coworkers where distinct 573 regions in admittance gain were noted between 0.25-0.1 Hz and 0.1-0.06 Hz (88; 89; 91). However, this 574 was not readily apparent during control conditions (88; 89; 91). As noted above, two distinct 575 components or stages in the RVR response in the time-domain were also reported by Drummond et al. 576
between 3 and 25 sec after a RPP step (24; 25; 27). 577
In addition to eliciting vasodilation, NO blunts vasoconstriction produced by G-protein coupled 578 agonists such as angiotensin II (ANG II), endothelin (ET-1) and the catecholamines (CAT) 579 norepinephrine or phenylephrine (9; 38; 40). Exaggerated vasoconstriction by one of these agonists 580 might explain the enhanced myogenic response during NOS inhibition. However, ANG II and CAT do 581 not potentiate the myogenic response in the time-domain (20; 35) or the frequency domain (1; 71; 80) 582 as markedly as that seen during NOS inhibition of NO production. On the other hand, O 2 -does 583 enhance the myogenic response by an action independent of NO (50). Thus, we conclude that NOS 584 inhibition leads to an exaggerated myogenic response that is likely mediated by reduced vasodilatory 585 activity from NO and/or enhanced O 2 -mediated vasoconstriction. 586
The incorporation of superoxide removal with tempol after NOS inhibition is an important component 587 of our studies as it probes the direct cause of the increased vascular reactivity associated with L-NAME 588 treatment. The actions of L-NAME may be readily explained by elimination of the vasodilatory actions of 589 NO, but our observations suggest a more complex explanation. The action of L-NAME on the myogenic 590 autoregulatory response was reversed by tempol in both the time-and frequency-domains. The 591 opposite actions of NO synthesis inhibition with L-NAME and O 2 -dismutation by tempol suggest 592 counteracting influences of NO and O 2 -on the myogenic mechanism. Such a paracrine-like interaction 593 was apparent during the initial but not the secondary stage of the myogenic response in our time-series 594 experiments. In addition, a similar interaction was suggested only at higher frequencies in the myogenic 595 range in spectral analyses of RBF autoregulation, which we have identified in Fig. 4B as stage 1 . 596
Collectively, these findings are consistent with the proposal that the inhibitory action of NO on the 597 myogenic response results from quenching of O 2 -in stage 1 of the myogenic response and does not 598 involve a direct vasodilatory action involving activation of soluble guanylyl cyclase (sGC) and cGMP 599 production. If this were not the case, one would expect the vasoconstrictor action of L-NAME to persist 600 after O 2 -dismutation with tempol, which was not observed. This is also supported by data showing that 601 tempol alone has a relatively minor effect on the autoregulatory response to a step increase in RPP 602 compared to the pronounced effect after NO inhibition (NG Moss and WJ Arendshorst, unpublished 603 observations). This proposed role for NO is at variance with a recent publication showing that an effect 604 of L-NAME on the myogenic response similar to that reported here was reversed by cGMP formation 605 induced by continual pharmacological stimulation of sGC (19) . Overall steady-state RBF autoregulation 606 efficiency was attenuated by up to 33%, although most investigators report that NO donors, L-arginine, 607 or acetylcholine do not affect the efficiency of overall steady-state autoregulation (28; 45; 67; 68) . bioavailability of both radicals and is thought to modulate afferent arteriolar reactivity to ANG II (12) . 636
Thus, when both are generated in physiologically relevant amounts, an excess of NO will produce the 637 same response as a deficiency in O 2 -. This might explain steady-state studies reporting no effect of 638 tempol on RPP-induced constriction of the afferent arteriole of the isolated, perfused hydronephrotic 639 kidney (69) or on steady-state autoregulation of RBF and medullary blood flow under basal conditions 640
(23). 641
We recognize that the use of tempol to inactivate the vasoconstrictor O 2 -by dismutation could result 642 in the generation of the vasodilator H 2 O 2 which may play a role in the vasodilatory response. However, 643
we believe that the renal hemodynamic actions of tempol are primarily due to dismutation of O 2 -and 644 the removal its vasoconstrictor influence rather than increased H 2 O 2 levels. This conclusion is based on 645 the published work of other investigators showing that the potentiating action of O 2 -on myogenic 646 vasoconstriction in arteries and arterioles during increased intraluminal pressure is inhibited by tempol 647 but not by catalase (26; 50). Also, the enhanced myogenic response of afferent arterioles of SHR are 648 normalized by the O 2 -scavenger tempol or by the Nox2 inhibitor gp91ds, findings that led to the 649 conclusion that Nox2-derived O 2 -may contribute to the enhanced myogenic response (76). In mice, 650 isolated afferent arterioles increased O 2 -production in response to increased luminal pressure which 651 magnified myogenic constriction and was inhibited by tempol but unaffected by catalase, even though 652 
